SOLICITATION NOTICE
Q -- Circulating Inflammation-related Markers for the Detection of Early-Stage Gastric Cancer
- Notice Date
- 7/13/2017
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP72608-24
- Archive Date
- 8/5/2017
- Point of Contact
- Kimesha Leake, Phone: 2402765669, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
kimesha.leake@nih.gov, jolomi.omatete@nih.gov
(kimesha.leake@nih.gov, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E134, Bethesda, MD 20892, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), plans to procure services to measure circulating levels of inflammation-related biomarkers in cases of early-stage gastric cancer and age- and sex-matched controls from Olink Proteomics AB, Uppsala Science Park, Uppsala, SE-751 83, SWEDEN This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. It will be awarded as a firm fixed price type contract. It has been determined that there are no opportunities to acquire green products or services for this procurement. The mission of DCEG is to conduct broad-based, high quality, high impact research to uncover the causes of cancer and the means of its prevention. DCEG maintains a national and international perspective, giving priority to emergent issues identified through epidemiologic, clinical, and laboratory observations, as well as to public health concerns identified by the NCI, Congress, regulatory agencies, and other appropriate bodies. The Division develops research resources and strategic partnerships in molecular epidemiology across NCI, NIH, and the global research community. The Division holds as its top priority the training and development of the next generation of scientists in cancer epidemiology and related fields. In Helicobacter pylori-related gastric cancer, mucosal colonization induces chronic inflammation that may progress to multifocal atrophy, intestinal metaplasia, dysplasia and cancer. Accordingly, circulating levels of inflammation and immunity molecules may be informative about carcinogenesis, either as markers of local tissue activity in gastric mucosa or as direct measures of relevant systemic effects. In order to evaluate utility for screening detection of early-stage gastric cancer, we will measure inflammation-related biomarkers in cases of asymptomatic gastric cancer that are discovered during screening endoscopy and age- and sex-matched controls. This study will provide etiologic insight about carcinogenic pathways and potentially identify predictive marker profiles applicable for risk stratification. This acquisition requires the services of Olink Proteomics AB to provide proximity extension assays for 92 markers. Olink's Multiplex Inflammation Panel is a proprietary test to measure these specific markers with minimal cross-reactivity in a single drop of biospecimen. Based on discussions with others in the field and market research, we have determined there are no other known companies that provide the same or equivalent test. In addition, results from this study need to be comparable to those available from previous DCEG studies using this technology. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 5:00 PM EST, on July 21, 2017. All responses and questions can be emailed to Kimesha Leake, Contract Specialist via electronic mail at kimesha.leake@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP72608-24 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP72608-24/listing.html)
- Record
- SN04579324-W 20170715/170714000231-e79f14a6867eb759229d567ef92f9722 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |